Barclays analyst Balaji Prasad lowered the firm’s price target on Pacira (PCRX) to $17 from $25 and keeps an Equal Weight rating on the shares. The company’s Q3 revenue missed consensus by 6%, with Exparel in-line and strong gross margin at 78%, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX: